Business
Kalytera Announces Extension of Maturity Date of Promissory Note
Kalytera Announces Extension of Maturity Date of Promissory Note.
About this update from Claritas Pharmaceuticals Inc.
[{"type":"text","content":"\n SAN FRANCISCO and TEL AVIV, Israel, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the \"Company\" or \"Kalytera\") today announced that, in accordance with the previously announced agreement between the Company and the former shareholders of the Company’s subsidiary, Talent Biotechs Ltd., the Company has agreed with the note holder of the secured promissory note in the approximate amount of USD $2 million in favor of such shareholders to extend the maturity date of the note until March 15, 2020. The Company does not intend to comment further or publicly discuss this matter until the Company has determined that further disclosure is appropriate or required by law. About Kalytera TherapeuticsKalytera Therapeutics, Inc. is pioneering the development of CBD therapeutics. Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of CBD medicines for a range of important unmet medical needs, with an initial focus on graft versus host disease GVHD. Website Home: https://kalytera.co/News and Insights: https://kalytera.co/news/Investors: https://kalytera.co/investors/ Cautionary StatementsNeither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release may contain certain forward-looking information and statements (\"forward-looking information\") within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation in respect of any product candidate, planned clinical trials, regulatory approval prospects, intellectual property objectives and other statements containing the words \"believes\", \"anticipates\", \"plans\", \"intends\", \"will\", \"should\", \"expects\", \"continue\", \"estimate\", \"forecasts\" and other similar expressions. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk that future clinical studies may not proceed as expected or may produce unfavourabl...